<DOC>
	<DOCNO>NCT00608829</DOCNO>
	<brief_summary>The objective study assess safety efficacy 45 mm TAG device subject aneurysms descend thoracic aorta .</brief_summary>
	<brief_title>GORE TAG® Thoracic Endoprosthesis - 45 mm Treatment Aneurysms Descending Thoracic Aorta</brief_title>
	<detailed_description />
	<mesh_term>Aneurysm</mesh_term>
	<mesh_term>Aortic Aneurysm</mesh_term>
	<mesh_term>Aortic Aneurysm , Thoracic</mesh_term>
	<criteria>1 . Presence Descending thoracic aortic aneurysm deem warrant surgical repair Fusiform ( ≥50 mm ) , Saccular ( diameter criterion ) 2 . All proximal and/or distal land zone inner diameter 3742 mm Diameter taper proximal distal landing zone ability use device different diameter compensate taper must within device size guide specification 3 . Proximal distal land zone length great 2.0 cm Landing zone must aneurysmal , dissect , heavily calcify , heavily thrombose 4 . Life expectancy &gt; 2 year 5 . Subject open surgical candidate define : Able tolerate thoracotomy American Society Anesthesiologists class IIV ( class V exclude ) New York Heart Association class IIII applicable ( class IV exclude ) 6 . Male infertile female 7 . Age great 21 year 8 . Able comply study protocol requirement , include followup 1 . Mycotic aneurysm 2 . Hemodynamically unstable aneurysm rupture 3 . Aortic dissection 4 . Planned occlusion leave carotid celiac artery 5 . Planned concomitant surgical procedure ( left subclavian transposition ) , major surgery within 30 day treatment date 6 . Myocardial infarction stroke within 6 week treatment 7 . Pretreatment creatinine &gt; 2.0 mg/dL 8 . Degenerative connective tissue disease , e.g . Marfan 's EhlerDanlos Syndrome 9 . Participation another drug device study within 1 year treatment 10 . History drug abuse within 6 month treatment</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>